Showing 2041 results
-
Clinical Trials /
-
Press release /Patients on Tasigna achieved rapid and high rates of molecular response with a very low rate of progression to advanced disease ENEST1st data confirm the favorable benefit/risk profile of…
-
Press release /The ALITHIOS open-label extension study showed continuous treatment with Kesimpta® (ofatumumab) for up to five years in relapsing multiple sclerosis (RMS) patients was associated with reduced risk of…
-
Press release /If approved in expected timeframe, Luxturna* (voretigene neparvovec) will be first and only gene therapy available in EU to treat a rare inherited retinal disease Children and adults…
-
Press release /In the updated analysis from ELIANA, Kymriah demonstrated an 82% remission rate within 3 months in pediatric patients with r/r ALL; relapse-free survival was 62% at 24 months, with median duration…
-
Press release /Lutathera treatment was associated with an ~80% reduction in the estimated risk of tumor progression or death vs comparator, regardless of baseline liver tumor burden[1] Lutathera treatment was…
-
Press release /If approved, Mayzent® (siponimod) will be the first and only oral treatment specifically indicated for patients with active secondary progressive multiple sclerosis (SPMS) in Europe[1]) CHMP…
-
Press release /Une approche unique en son genre dans l'industrie de la santé, qui vise à rendre 15 médicaments plus facilement disponibles et plus accessibles pour traiter les maladies cardiovasculaires, le diabète…
-
Press release /Data show adult patients may achieve durable response rates, with 13 of 19 evaluable patients with relapsed/refractory non-Hodgkin lymphomas responding to therapy[1] Recent milestones for…
-
Press release /In Phase II studies, Zykadia (ceritinib) shrank tumors in patients with ALK+ NSCLC; comparable overall response in those with or without brain metastases[1],[2] Tafinlar (dabrafenib) and…